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Abstract
Non-inherited maternal antigens encoded by specific HLA-DRB1  alleles (NIMA) have been
implicated as a rheumatoid arthritis (RA) risk factor. Using genotype data from North American
Rheumatoid Arthritis Consortium study participants and the maternal-fetal genotype
incompatibility (MFG) test, we find evidence for offspring allelic effects but no evidence for NIMA
as a RA risk factor. We discuss possible reasons why our result conflicts with several previous
studies (including one of our own) that used RA patients from northern Europe.
Background
Rheumatoid arthritis (RA) is highly associated with HLA-
DRB1  *0101, *0102, *0401, *0404, *0405, *0408,
*0423, *10, *1001, *1402, and *1406 alleles that encode
a shared epitope (SE) [1]. However, as many as 30% of the
patients do not carry SE coding alleles [1] and an associa-
tion between non-inherited maternal SE HLA-DRB1 anti-
gen coding alleles (NIMA) and RA also has been observed
[2-5]. One explanation for the latter finding is that NIMA
may be involved in RA pathogenesis through microchi-
mera formation in offspring who do not have SE coding
alleles [2]. However, other studies have not found a signif-
icant NIMA effect [6-8].
Hsieh et al. [3] demonstrated that the maternal-fetal gen-
otype incompatibility (MFG) test [9,10] allows the joint
estimation of the offspring allelic and NIMA effects as a
RA risk factor and is robust to population stratification.
The current study applies the MFG test to HLA-DRB1 gen-
otype data from the North American Rheumatoid Arthri-
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tis Consortium (NARAC) study to test NIMA as a risk
factor for RA.
Methods
Statistical modeling: the MFG test
The MFG test models the joint distribution of parental
and offspring genotypes given the number of affected off-
spring in nuclear families as
where for family i = 1,..., N,   denote
the genotypes of the ni offspring, in which ki are affected;
 denote parental genotypes, in which
 and   are maternal and paternal genotypes,
respectively;   denotes the event that
ki offspring are affected [4,5]. Phenotypes of the unaf-
fected offspring are not used in the likelihood.
Using Bayes' theorem and assuming siblings' phenotypes
are independent given parental genotypes, likelihood Eq.
(1) is parameterized in terms of penetrance functions and
population mating type frequencies [3,9]. As in Hsieh et
al. [3], we model the penetrances as
pr(D|Gc, Gp) = p × μI[M] × ρ1
I[Z = 1] × ρ2
I[Z = 2] ,( 2 )
where I [·] is the indicator function, M is the event that
the offspring does not inherit an SE coding allele carried
by the mother (i.e., NIMA), and Z denotes the number of
SE coding alleles present in the offspring genotype. The
parameter p denotes the population baseline disease inci-
dence rate, which ultimately cancels from Eq. (1). The
parameter μ is the relative risk due to NIMA; ρ1 and ρ2 are
the relative risks when one or two copies of the SE coding
allele are present in the offspring genotype, respectively,
relative to zero copies. Note that the relative risks (μ, ρ1,
ρ2) range from 0 to infinity, and each have a null value of
1. The numerical maximization of the log-likelihood is
better conditioned when we use the natural logarithm of
the relative risks as parameters so we actually estimate α =
log(μ), β1 = log(ρ1), and β2 = log(ρ2) [9]. Each of these
parameters, α, β1, and β2, are therefore defined on the real
line from negative infinity to infinity and each have a null
value of zero.
Because we assume that all SE coding alleles confer the
same risk to RA susceptibility (as was assumed in earlier
studies [2-8]), the model reduces to two alleles that we
denote as S for the SE coding risk allele and N for the non
SE coding allele. Thus, there are three possible genotypes
(S/S,  S/N, and N/N). The penetrance function as
expressed by Eq. (2) is short-hand for three mutually
exclusive maternal-offspring genotype combinations in
which the indicator functions determine which relative
risk corresponds to the genotype combination. These
mutually exclusive combinations are: the offspring carries
two copies of the S allele; the offspring carries one copy of
the S allele; and the offspring does not carry S allele but
the mother does. Each of these combinations has an asso-
ciated risk that we define in a standard manner, that is, as
relative to a reference category in which both the offspring
and mother are N/N.
Assuming mating symmetry under the null hypothesis,
there are six possible mating types [10]. Neither Hardy-
Weinberg equilibrium nor random mating is assumed.
Data from families with incomplete parental genotypes
are included in Eq. (1) by assuming the genotypes are
missing at random and summing over all possible paren-
tal genotypes [9,11]. Hypothesis tests of offspring allelic
or of NIMA effects use a likelihood-ratio test statistic,
whose distribution is asymptotically chi-square.
The NARAC data set
Of the four GAW15 RA study samples, only the NARAC
data set was suitable for this analysis because at least some
parental HLA-DRB1 genotypes must be available to test
for NIMA effects. The ethnic background of the NARAC
families is representative of United States and Canadian
families affected with RA (predominately Caucasian with
African, Hispanic, Native American, and Asian minori-
ties).
Before recoding the alleles into S and N, we used the ped-
igree trimming option of Mendel (version 6.5.0) to
remove individuals without HLA-DRB1  genotypes who
are not necessary to define the relationships among geno-
typed individuals [12,13]. We then tested for genotyping
errors using the mistyping analysis available in Mendel
version 6.5.0 [13,14] and found that the HLA-DRB1 error
rate was less than 1%. Individuals' genotypes that were in
error were omitted and when several family members
could be in error, the entire family's HLA-DRB1 genotypes
were omitted. Most of the families are nuclear families;
however there are a few extended families. For each
extended pedigree, a single nuclear family was selected
using the following protocol: whenever a nuclear family
has complete parental genotypes available, they are
selected over those families with zero or one parent geno-
typed. Whenever multiple nuclear families within the
extended pedigree have the same parental genotype avail-
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ability, one of the nuclear families is randomly selected.
At this point, there were 708 nuclear families.
About half the families have neither parent genotyped.
These families provide very little power for detecting
maternal-fetal genotype interactions [11] and were omit-
ted. The remaining number of nuclear families was 318.
We then recoded the alleles. The resolution of 119 indi-
viduals' HLA-DRB1 genotypes is too low to allow certain
classification of their alleles as S or N. For example the
allele *01 could be *0101 (S) or *0103 (N). These ambig-
uous genotypes were treated as missing in the analysis.
The final data set had 263 nuclear families with at least
one parent and one affected offspring genotyped. The dis-
tribution of affected offspring and genotyped parents is
given in Table 1. There are a total of 517 affected offspring
(393 female and 124 male) in these families. To test
whether we introduced a bias by our family selection
scheme, we compared the genotype distribution of
affected offspring from the families used in the analysis to
the genotype distribution of affected offspring from the
excluded families. Specifically, we randomly selected one
affected offspring per included family and one affected
offspring per excluded family and compared the distribu-
tions using a Fisher exact test. We found that the genotype
distributions were not significantly different (p = 0.946).
Results
Inference
We fit three models by placing different constraints on the
parameters. These models are compared by constructing
likelihood-ratio test statistics. Comparison of Models 1 (α
= β1 = β2 = 0) and 2 (α = 0) in Table 2 reveals a highly sig-
nificant offspring SE allelic effect on RA risk (  = 128.1,
p = 1.5 × 10-28). The relative risk for individuals with S/N
is ρ1 = 4.3 and the relative risk for individuals with S/S is
ρ2 = 12.7, similar in magnitude to the results of earlier
association studies (see for example [15,16]). Compari-
son of Models 2 (α = 0) and 3 (no parameter restrictions)
shows there is no evidence for the NIMA effect on RA risk
in the presence of offspring allelic effects (  = 0.0172, p
= 0.8956).
Power
One possible explanation for our failure to find evidence
for the NIMA effect is that our sample size is too small.
The earlier studies found the MFG effect to be ~4, approx-
imately equal to the S/N risk to offspring [2-5]. We simu-
lated 1000 data sets and found that there is 80% power to
detect an MFG effect size of 3.5 with 63 families each hav-
ing two affected offspring and completely genotyped par-
ents. Our actual study sample has power to detect even
smaller effect sizes because the additional 200 families
with only one parent genotyped substantially increase the
power [11].
Discussion
MFG incompatibility results when specific maternal-fetal
genotype combinations produce an adverse effect on the
developing fetus that ultimately increases offspring dis-
ease risk. The exposure of fetuses who do not carry SE cod-
ing alleles to a maternal SE antigen is an example of a
putative MFG incompatibility event and so can be exam-
ined using the MFG test.
The highly significant offspring allelic effects are consist-
ent with numerous studies [3,15,16]. However, we did
not find any evidence of a NIMA effect. Although we can
not exclude the possibility that small NIMA effects were
missed, low power is not a reason for the failure to detect
moderate NIMA effects. Our simulation results show that
we could detect a NIMA effect that is less than the effect
size observed in earlier studies [2-5]. Although the
NARAC families are ethnically diverse, population stratifi-
cation also is not a concern as the MFG test is robust to its
effects [3,10,11].
There were originally 708 nuclear families available in the
NARAC data set. After excluding families without parental
genotypes and individuals with low-resolution HLA-
DRB1 genotypes, only 263 nuclear families were used in
our analysis. However when the genotypes are missing at
random, it has been shown that MFG test produces unbi-
ased parameter estimates and accurate hypothesis tests
when only approximately 25% of the families in the sam-
ple have both parental genotypes [11]. The missing-at-
χ2
2
χ1
2
Table 2: Offspring shared epitope and NIMA effects as estimated 
by the MFG test
Model α = logμ 
(std err)
β1 = logρ1 
(std err)
β2 = logρ2 
(std err)
log likelihood
10 00 - 7 3 1 . 0 9 2 6
2 0 1.462(0.188) 2.538(0.239) -667.0471
3 -0.0423 (0.324) 1.436 (0.272) 2.511 (0.317) -667.0385
Table 1: Distribution of affected offspring among the 263 
families
No. 
affected 
siblings
Families with 
both parents 
genotyped
Families with only 
mothers 
genotyped
Families with only 
fathers genotyped
16 1 8 6
2 53 135 25
34 1 2 3
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random assumption is reasonable in this study. Therefore,
the remaining 263 families provide valid, unbiased results
even though more than half of the original NARAC fami-
lies are excluded.
The following reasons might account for the failure to
find a significant MFG incompatibility effect: a) the previ-
ous studies with positive findings [2-5] could represent
type I errors, or the maternal or offspring effects at other
HLA loci could have been misattributed to a HLA-DRB1
NIMA effect (an issue of model misspecification); b) HLA-
DRB1 is difficult to accurately genotype and mistyping
could lead to both false-positive and negative NIMA
results; c) there could be population differences in the sus-
ceptibility to microchimera; d) differences in ascertain-
ment or diagnostic criteria used in the different studies
might also contribute to the variability in the results. The
NARAC families are multi-case families and these families
may have a different genetic background than single-case
families [5].
Conclusion
The MFG test [3,9-11] can be used to determine whether
the  HLA-DRB1  NIMA effect is a risk factor for RA.
Although we can not rule out NIMA as a RA risk factor of
small effect in the NARAC families, we find no evidence
for NIMA as a RA risk factor of moderate effect.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Acknowledgements
This investigation was supported in part by NIH grants GM53275 and 
HL28481.
This article has been published as part of BMC Proceedings Volume 1 Sup-
plement 1, 2007: Genetic Analysis Workshop 15: Gene Expression Analysis 
and Approaches to Detecting Multiple Functional Loci. The full contents of 
the supplement are available online at http://www.biomedcentral.com/
1753-6561/1?issue=S1.
References
1. Newton JL, Harney SM, Wordsworth BP, Brown MA: A review of
the MHC genetics of rheumatoid arthritis.  Genes Immun 2004,
5:151-157.
2. Harney S, Newton J, Milicic A, Brown MA, Wordsworth BP: Non-
inherited maternal HLA alleles are associated with rheuma-
toid arthritis.  Rheumatology 2003, 42:171-174.
3. Hsieh H, Palmer CGS, Harney S, Newton JL, Woodsworth P, Brown
MA, Sinsheimer JS: The v-MFG test: Investigating maternal, off-
spring, and maternal-fetal genetic incompatibilities effects
on disease and viability.  Genet Epidemiol 2006, 30:333-347.
4. ten Wolde S, Breedveld FC, de Vires RR, D'Amaro J, Rubenstein P,
Schreuder GMTh, Claas FHJ, van Rood JJ: Influence of non-inher-
ited maternal HLA antigens on occurrence of rheumatoid
arthritis.  Lancet 1993, 341:200-202.
5. van der Horst-Bruinsma IE, Haxes JM, Schreuder GM, Radstake TR,
Barrera P, van de Putte LB, Mustamu D, van Schaardenburg D, Breed-
veld FC, de Vries RR: Influence of non-inherited maternal HLA-
DR antigens on susceptibility to rheumatoid arthritis.  Ann
Rheum Dis 1998, 57:672-675.
6. Silman AJ, Hay EM, Worthington J, Thomson W, Pepper L, Davidson
J, Dyer PA, Ollier WE: Lack of influence of non-inherited
maternal HLA-DR alleles on susceptibility to rheumatoid
arthritis.  Ann Rheum Dis 1995, 54:311-313.
7. Barrera P, Balsa A, Alves H, Westhovens R, Maenaut K, Cornélis F,
Fritz P, Bardin T, de Almeida G, Lopes-Vaz A, Pascual Salcedo D, de
la Concha EG, Radstake TR, van de Putte LB, Migliorini P,
Prud'homme JF, Charron D, Spyropoulou M, Mendes A, Spaepen M,
Martinez M, Lepage V, Stravopoulos C: Noninherited maternal
antigens do not play a role in rheumatoid arthritis suscepti-
bility in Europe. European Consortium on Rheumatoid
Arthritis Families.  Arthritis Rheum 2000, 43:758-764.
8. Barrera P, Balsa A, Alves H, Westhovens R, Maenaut K, Cornélis F,
Fritz P, Bardin T, Ceu Maia M, Lopes-Vaz A, Pascual Salcedo D, de la
Concha E, Radstake T, van de Putte LB, Migliorini P, Prudhomme JF,
Charron D, Spyropoulou M, Mendes A, Spaepen M, Martinez M, Sta-
vropoulos C, European Consortium on Rheumatoid Arthritis Fami-
lies:  Noninherited maternal antigens do not increase the
susceptibility for familial rheumatoid arthritis. European
Consortium on Rheumatoid Arthritis Families.  J Rheumatol
2001, 28:968-974.
9. Kraft P, Palmer CGS, Woodward JA, Turunen JA, Minassian S, Paunio
T, Lonnqvist J, Peltonen L, Sinsheimer JS: RHD Maternal-Fetal
genotype incompatibility and schizophrenia: Extending the
MFG test to include multiple siblings and birth order.  Eur J
Hum Gen 2004, 12:192-198.
10. Sinsheimer JS, Palmer CGS, Woodward JA: Detecting genotype
combinations that increase risk for disease: The Maternal-
Fetal genotype incompatibility test.  Gen Epidemiol 2003,
24:1-13.
11. Hsieh HJ, Palmer CG, Sinsheimer JS: Allowing for missing data at
highly polymorphic genes when testing for maternal, off-
spring and maternal-fetal genotype incompatibility effects.
Hum Hered 2006, 62:165-174.
12. Lange K, Sinsheimer JS: The pedigree trimming problem.  Hum
Hered 2004, 58:108-111.
13. Lange K, Cantor R, Horvath S, Perola M, Sabatti C, Sinsheimer J, Sobel
E:  Mendel version 4.0: A complete package for the exact
genetic analysis of discrete traits in pedigree and population
data sets.  Amer J Hum Gen 2001, 69(S):A1886.
14. Sobel E, Papp JC, Lange K: Detection and integration of genotyp-
ing errors in statistical genetics.  Amer J Hum Gen 2002,
70:496-508.
15. Hall FC, Weeks DE, Camilleri JP, Williams LA, Amos N, Darke C,
Gibson K, Pile K, Wordsworth BP, Jessop JD: Influence of the
HLA-DRB1 locus on susceptibility and severity in rheuma-
toid arthritis.  QJM 1996, 89:821-829.
16. Meyer JM, Evans TI, Small RE, Redford TW, Han J, Singh R, Moxley G:
HLA-DRB1 genotype influence risk for and severity of rheu-
matoid arthritis.  J Rheumatol 1999, 26:1024-1034.